Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Decaprenylphosphoryl-beta-D-ribose oxidase (DprE1) is an essential flavoenzyme in *Mycobacterium tuberculosis*. It catalyzes a key step in the biosynthesis of decaprenyl-phospho-arabinose (DPA), an arabinose donor required for the synthesis of arabinogalactan and lipoarabinomannan. DprE1 functions with its partner protein DprE2 and is a validated drug target for tuberculosis.
Inhibition of DprE1 prevents the synthesis of arabinogalactan and lipoarabinomannan, essential components of the mycobacterial cell wall.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Decaprenylphosphoryl-beta-D-ribose oxidase (DprE1).